keyword
https://read.qxmd.com/read/38448188/-multidisciplinary-expert-consensus-on-the-clinical-rational-application-of-different-formulations-of-amphotericin-b-2024-edition
#1
JOURNAL ARTICLE
(no author information available yet)
Amphotericin B (AmB) is a broad-spectrum and potent polyene antifungal drug for the treatment of invasive fungal diseases (IFDs). Currently, amphotericin B deoxycholate (AmB-D) and three AmB lipid formulations, namely liposomal amphotericin B (L-AmB), amphotericin B colloidal dispersion (ABCD), and amphotericin B lipid complex (ABLC) are available for clinical use. In view of clinical concerns and misperceptions in the selection of different formulations of AmB, the present consensus summarized their pharmaceutical characteristics, antifungal mechanism, pharmacokinetics/phamacodynamics, drug interactions, indications, dosage, local administration, and adverse reactions based on the latest clinical research evidence, guidelines, and clinical experience...
March 1, 2024: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
https://read.qxmd.com/read/33139650/rezafungin-mechanisms-of-action-susceptibility-and-resistance-similarities-and-differences-with-the-other-echinocandins
#2
REVIEW
Guillermo Garcia-Effron
Rezafungin (formerly CD101) is a new β-glucan synthase inhibitor that is chemically related with anidulafungin. It is considered the first molecule of the new generation of long-acting echinocandins. It has several advantages over the already approved by the Food and Drug Administration (FDA) echinocandins as it has better tissue penetration, better pharmacokinetic/phamacodynamic (PK/PD) pharmacometrics, and a good safety profile. It is much more stable in solution than the older echinocandins, making it more flexible in terms of dosing, storage, and manufacturing...
November 1, 2020: Journal of Fungi (Basel, Switzerland)
https://read.qxmd.com/read/32386239/a-pharmacokinetic-pharmacodynamic-study-of-a-single-dose-of-febuxostat-in-healthy-subjects
#3
JOURNAL ARTICLE
Bishoy Kamel, Garry G Graham, Sophie L Stocker, Zhixin Liu, Ken M Williams, Jane E Carland, Kevin D Pile, Richard O Day
AIMS: To examine the pharmacokinetic-phamacodynamic (PK-PD) relationships of plasma febuxostat and serum urate and the effect of a single dose of the drug on renal excretion and fractional clearance of urate (FCU). METHODS: Blood and urine samples were collected at baseline and up to 145 h following administration of febuxostat (80 mg) to healthy subjects (n=9). Plasma febuxostat and serum and urinary urate and creatinine concentrations were determined. Febuxostat pharmacokinetics were estimated using a two-compartment model with first order absorption...
May 9, 2020: British Journal of Clinical Pharmacology
https://read.qxmd.com/read/27009113/growth-hormone-research-society-perspective-on-the-development-of-long-acting-growth-hormone-preparations
#4
JOURNAL ARTICLE
Jens Sandahl Christiansen, Philippe F Backeljauw, Martin Bidlingmaier, Beverly M K Biller, Margaret C S Boguszewski, Felipe F Casanueva, Philippe Chanson, Pierre Chatelain, Catherine S Choong, David R Clemmons, Laurie E Cohen, Pinchas Cohen, Jan Frystyk, Adda Grimberg, Yukihiro Hasegawa, Morey W Haymond, Ken Ho, Andrew R Hoffman, Jeff M P Holly, Reiko Horikawa, Charlotte Höybye, Jens Otto L Jorgensen, Gudmundur Johannsson, Anders Juul, Laurence Katznelson, John J Kopchick, K O Lee, Kuk-Wha Lee, Xiaoping Luo, Shlomo Melmed, Bradley S Miller, Madhusmita Misra, Vera Popovic, Ron G Rosenfeld, Judith Ross, Richard J Ross, Paul Saenger, Christian J Strasburger, Michael O Thorner, Haim Werner, Kevin Yuen
OBJECTIVE: The Growth Hormone (GH) Research Society (GRS) convened a workshop to address important issues regarding trial design, efficacy, and safety of long-acting growth hormone preparations (LAGH). PARTICIPANTS: A closed meeting of 55 international scientists with expertise in GH, including pediatric and adult endocrinologists, basic scientists, regulatory scientists, and participants from the pharmaceutical industry. EVIDENCE: Current literature was reviewed for gaps in knowledge...
June 2016: European Journal of Endocrinology
https://read.qxmd.com/read/25657334/magnetic-resonance-spectroscopy-for-detection-of-choline-kinase-inhibition-in-the-treatment-of-brain-tumors
#5
JOURNAL ARTICLE
Manoj Kumar, Sean P Arlauckas, Sona Saksena, Gaurav Verma, Ranjit Ittyerah, Stephen Pickup, Anatoliy V Popov, Edward J Delikatny, Harish Poptani
Abnormal choline metabolism is a hallmark of cancer and is associated with oncogenesis and tumor progression. Increased choline is consistently observed in both preclinical tumor models and in human brain tumors by proton magnetic resonance spectroscopy (MRS). Thus, inhibition of choline metabolism using specific choline kinase inhibitors such as MN58b may be a promising new strategy for treatment of brain tumors. We demonstrate the efficacy of MN58b in suppressing phosphocholine production in three brain tumor cell lines...
April 2015: Molecular Cancer Therapeutics
https://read.qxmd.com/read/24664666/pharmacogenetics-of-antiplatelet-therapy
#6
REVIEW
Patrick L Daly, Richard C Becker
There has been substantial progress toward understanding and investigating the specific genetic factors that influence interindividual variations in platelet-directed therapy. There has also been substantial progress toward better understanding of the pharmacogenetics of drug metabolism and phamacodynamic response to platelet antagonists. We summarize the relationship between genetic polymorphisms, response to platelet antagonists, and clinical impact on patient treatment for the commonly used antiplatelet drugs...
May 2014: Current Atherosclerosis Reports
https://read.qxmd.com/read/23299388/sustained-inhibition-of-deacetylases-is-required-for-the-antitumor-activity-of-the-histone-deactylase-inhibitors-panobinostat-and-vorinostat-in-models-of-colorectal-cancer
#7
JOURNAL ARTICLE
Peter M Wilson, Melissa J Labonte, Shelby C Martin, Stephanie T Kuwahara, Anthony El-Khoueiry, Heinz-Josef Lenz, Robert D Ladner
Despite compelling preclinical data in colorectal cancer (CRC), the efficacy of HDACIs has been disappointing in the clinic. The goal of this study was to evaluate the effectiveness of vorinostat and panobinostat in a dose- and exposure-dependent manner in order to better understand the dynamics of drug action and antitumor efficacy. In a standard 72 h drug exposure MTS assay, notable concentration-dependent antiproliferative effects were observed in the IC50 range of 1.2-2.8 μmol/L for vorinostat and 5.1-17...
August 2013: Investigational New Drugs
https://read.qxmd.com/read/22256752/-preparation-and-pharmacodynamics-studies-on-anti-inflammatory-effect-of-catechu-gel
#8
JOURNAL ARTICLE
Xiaoling Zheng, Caihong Zheng
OBJECTIVE: To prepare the gel of Chinese medicine catechu,study its release mechanism in vitro and observe the anti-inflammatory activity in rats. METHOD: Using the amount of catechin and epicatechin in dry extract as major evaluation factors, orthogonal experiment was carried out to investigate four influential factors of the ethanol concentration, ratio of raw material to solvent, ultrasonic time and extraction temperature. The catechu gel was prepared by using carbomer-940 as the gel base, and triethanomine as neutralizer...
September 2011: Zhongguo Zhong Yao za Zhi, Zhongguo Zhongyao Zazhi, China Journal of Chinese Materia Medica
https://read.qxmd.com/read/21545609/liraglutide-once-daily-glp-1-agonist-for-the-treatment-of-type-2-diabetes
#9
REVIEW
Gina J Ryan, Yolanda Hardy
WHAT IS KNOWN AND OBJECTIVE: The prevalence of diabetes is increasing worldwide. Over the recent years, new discoveries have led to the development of new pharmacological agents targeting the incretin hormones gastric inhibitory peptide (GIP) and glucagon-like peptide-1 (GLP-1). These agents, called incretin-mimetics, are the newest agents added to the diabetes treatment options. The purpose of this article is to review the relevant literature on the chemistry, pharmacology, pharmacokinetics, metabolism, clinical trials, safety, drug interactions and place in therapy of liraglutide in the treatment of type 2 diabetes...
June 2011: Journal of Clinical Pharmacy and Therapeutics
https://read.qxmd.com/read/21250819/synthesis-hydrolysis-studies-and-phamacodynamic-profiles-of-amide-prodrugs-of-dexibuprofen-with-amino-acids
#10
JOURNAL ARTICLE
Arun Rasheed, C K Ashok Kumar, Ashutosh Mishra
The present investigation deals with the synthesis of novel prodrugs of dexibuprofen with amino acids with an aim to achieve potent anti-inflammatory activity and less gastrointestinal toxicity. Structures of synthesized compounds were confirmed by spectral and elemental analyses. In vitro hydrolytic studies in simulated intestinal fluid, 80% plasma and rat faecal matter showed satisfactory release of dexibuprofen due to enzymatic cleavage. The synthesized prodrugs were evaluated for anti-inflammatory activity, analgesia, ulcerogenicity and histopathology...
October 2011: Journal of Enzyme Inhibition and Medicinal Chemistry
https://read.qxmd.com/read/20429673/pharmacologic-evaluation-of-ospemifene
#11
REVIEW
Jamie L McCall, Michael W DeGregorio
IMPORTANCE OF THE FIELD: Millions of women worldwide suffer from vulvovaginal atrophy (VVA) associated with menopause, and many women report that this adversely affects their quality of life. Ospemifene is a non-hormonal estrogen receptor agonist/antagonist effective in the treatment of VVA. Although similar in structure to other estrogen receptor agonists/antagonists that have antagonistic effects on the vagina, ospemifene has an estrogen-like effect on vaginal epithelium. This review focuses on ospemifene including its pharmacologic properties, clinical efficacy and safety...
June 2010: Expert Opinion on Drug Metabolism & Toxicology
https://read.qxmd.com/read/20228044/design-synthesis-hydrolysis-kinetics-and-phamacodynamic-profiles-of-histidine-and-alanine-conjugates-of-aceclofenac
#12
COMPARATIVE STUDY
Arun Rasheed, C K Ashok Kumar
The gastrointestinal toxicity associated with aceclofenac can be reduced by condensing its carboxylic acid group with methyl esters of amino acids like histidine and alanine to give amide linkage by the Schotten-Baumann method. Physicochemical characterization of the conjugates was carried out by various analytical and spectral methods. The synthesized conjugates were also subjected to in vitro hydrolysis in simulated gastric fluid (SGF) at pH 1.2, simulated intestinal fluid (SIF) at pH 7.4 and SIF+ 80% human plasma at pH 7...
March 2010: Acta Pharmaceutica
https://read.qxmd.com/read/19616110/a-framework-to-assess-the-translation-of-safety-pharmacology-data-to-humans
#13
JOURNAL ARTICLE
Jean-Pierre Valentin, Russell Bialecki, Lorna Ewart, Tim Hammond, Derek Leishmann, Silvana Lindgren, Vicente Martinez, Chris Pollard, Will Redfern, Rob Wallis
This article outlines a strategy for collecting accurate data for the determination of the sensitivity, specificity and predictive value of safety pharmacology models. This entails performing a retrospective analysis on commonly used safety pharmacology endpoints and an objective assessment of new non-clinical models. Such assessments require a systematic quantitative analysis of safety pharmacology parameters as well as clinical Phase I adverse events. Once the sensitivity, specificity and predictive capacity of models have been determined, they can be aligned within specific phases of the drug discovery and development pipeline for maximal impact, or removed from the screening cascade altogether...
September 2009: Journal of Pharmacological and Toxicological Methods
https://read.qxmd.com/read/19497287/in-vitro-antimalarial-interactions-between-mefloquine-and-cytochrome-p450-inhibitors
#14
JOURNAL ARTICLE
Raewadee Wisedpanichkij, Wanna Chaijaroenkul, Piyanan Sangsuwan, Jintana Tantisawat, Kanyarat Boonprasert, Kesara Na-Bangchang
The treatment and control of malaria is becoming increasingly difficult due to resistance of Plasmodium falciparum strains resistance to commonly used antimalarials. Combination therapy is currently the strategy for combating multi-drug resistant falciparum malaria, through exploiting phamacodynamic synergistic effect and delaying the emergence of drug resistance. The objective of the present study was to investigate antimalarial activity of inhibitors of cytochrome P450 (CYP) enzyme including their interactions with the antimalarial mefloquine against chloroquine-resistant (K1) and chloroquine-sensitive (3D7) P...
October 2009: Acta Tropica
https://read.qxmd.com/read/19000855/-clinical-implications-of-antibiotic-pharmacokinetic-pharmacodynamic-parameters
#15
JOURNAL ARTICLE
R Cohen
The progress in the knowledge of antibiotic action mechanisms have led to determine phamacodynamic/pharmacokinetic (PK/PD) parameters predictive of antibiotic efficacy in bacterial infections. These parameters could vary according to the antibiotic compound, the bacterial specie implicated, the localization of the infection, the severity of the disease. The serum PK/PD parameters are predictive of efficacy in several infections (respiratory, skin, bone) and become a major criterion for selecting antibiotics in clinical practice...
October 2008: Archives de Pédiatrie: Organe Officiel de la Sociéte Française de Pédiatrie
https://read.qxmd.com/read/18520598/the-role-of-cytochrome-p2c19-in-r-warfarin-pharmacokinetics-and-its-interaction-with-omeprazole
#16
RANDOMIZED CONTROLLED TRIAL
Tsukasa Uno, Katsuyoshi Sugimoto, Kazunobu Sugawara, Tomonori Tateishi
Previous studies reported omeprazole to be an inhibitor of cytochrome P450 (CYP) 2C19 and suggested the pharmacokinetic interaction of omeprazole with R-warfarin. The aim of this study was to compare possible effects of omeprazole on the stereoselective pharmacokinetics and pharmacodynamics of warfarin between CYP2C19 genotypes. Seventeen subjects, of whom 10 were homozygous extensive metabolizers (hmEMs) and seven were poor metabolizers (PMs) for CYP2C19, were enrolled in this randomized crossover study, and they ingested 20 mg omeprazole or placebo once daily for 11 days...
June 2008: Therapeutic Drug Monitoring
https://read.qxmd.com/read/17956820/-pharmacokinetics-and-pharmacodynamics-of-antimicrobial-therapy-used-in-child-osteoarticular-infections
#17
REVIEW
R Cohen, E Grimprel
The progress in the knowledge of antibiotic action mechanisms have led to determine phamacodynamic/pharmacokinetic (PK/PD) parameters predictive of antibiotic efficacy in bacterial infections. According to the antibiotic compound, the implicated bacterial specie, the localization of the infection, the severity of the disease, these parameters could vary. The PK/PD parameters described in this paper focus only on blood compartment and S. aureus, (main bacteria implicated in bone and joint tissue infections)...
October 2007: Archives de Pédiatrie: Organe Officiel de la Sociéte Française de Pédiatrie
https://read.qxmd.com/read/14673582/assessing-dopaminergic-function-in-parkinson-s-disease-levodopa-kinetic-dynamic-modeling-and-spect
#18
COMPARATIVE STUDY
Manuela Contin, Paolo Martinelli, Roberto Riva, Maurizio Dondi, Stefano Fanti, Cinzia Pettinato, Cesa Scaglione, Fiorenzo Albani, Agostino Baruzzi
Levodopa pharmacokinetic-phamacodynamic (PK-PD) modeling may be able to test the functional integrity of the nigrostriatal dopaminergic system in Parkinson's disease (PD). [(123)I]-FP-CIT SPECT imaging of striatal dopamine transporters has also been introduced for the evaluation of presynaptic dopaminergic homeostasis. We aimed to assess the intrapatient relation between levodopa PK-PD and SPECT measures of dopaminergic function in PD. Thirty-five PD patients, 1 to 4 on the Hoehn and Yahr (H&Y) scale, enrolled in the study...
December 2003: Journal of Neurology
https://read.qxmd.com/read/12988458/-phamacodynamic-investigations-on-the-sodium-salts-of-salicylic-gentisic-p-amino-salicylic-and-p-amino-benzoic-acids
#19
JOURNAL ARTICLE
J DELPHAUT
No abstract text is available yet for this article.
March 1952: Comptes Rendus des Séances de la Société de Biologie et de Ses Filiales
https://read.qxmd.com/read/12525234/use-of-low-molecular-weight-heparins-in-the-management-of-acute-coronary-artery-syndromes-and-percutaneous-coronary-intervention
#20
REVIEW
Graham C Wong, Robert P Giugliano, Elliott M Antman
CONTEXT: Low-molecular-weight heparins (LMWHs) possess several potential pharmacological advantages over unfractionated heparin as an antithrombotic agent. OBJECTIVE: To systematically summarize the clinical data on the efficacy and safety of LMWHs compared with unfractionated heparin across the spectrum of acute coronary syndromes (ACSs), and as an adjunct to percutaneous coronary intervention (PCI). DATA SOURCES: We searched MEDLINE for articles from 1990 to 2002 using the index terms heparin, enoxaparin, dalteparin, nadroparin, tinzaparin, low molecular weight heparin, myocardial infarction, unstable angina, coronary angiography, coronary angioplasty, thrombolytic therapy, reperfusion, and drug therapy, combination...
January 15, 2003: JAMA
keyword
keyword
50775
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.